PUBLICATION OF PRICING SUPPLEMENT

Lloyds Bank PLC
31 August 2023
 

NOTICE

 

Publication of PRICING SUPPLEMENT

 

 

LLOYDS BANK PLC

(the Issuer)

 

Publication of PRICING SUPPLEMENT

The following Pricing Supplement under the €60 billion Global Covered Bond Programme of Lloyds Bank plc are available for viewing:

CHF 440,000,000 1.870 per cent. Series 2023-3 Fixed Rate Covered Bonds due August 2027

To view the Pricing Supplement, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/9800K_1-2023-8-31.pdf

The Pricing Supplement has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Investor Relations:

 

Douglas Radcliffe

Group Investor Relations Director

Tel:      +44 (0) 20 7356 1571

E-mail: douglas.radcliffe@lloydsbanking.com

 

Corporate Affairs:

 

Matt Smith

Head of Media Relations

Tel:       +44 (0) 20 7356 3522

E-mail:   matt.smith@lloydsbanking.com

 

Debt Investor Relations:

 

Pascale Dorey

Debt Investor Relations

Tel:        +44 (0) 20 7354 7402

E-mail: pascale.dorey@lloydsbanking.com

Lloyds Bank plc

Registered Office

25 Gresham Street

London EC2V 7HN



Disclaimer - Intended Addressees

Please note that the information contained in this announcement and the Pricing Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and Pricing Supplement are not addressed.  Prior to relying on the information contained in this announcement and the Pricing Supplement, you must ascertain from the Base Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Pricing Supplement.

In particular, this announcement and the Pricing Supplement do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful.  This announcement and the Pricing Supplement are not for distribution in the United States or to U.S. persons (as defined below).  The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the Securities Act) or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements.  The securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the Securities Act) except pursuant to registration or an exemption from the registration requirements of the Securities Act.  There will be no public offering of the securities in the United States. For a description of the restrictions on offers and sales of the securities described herein, please refer to the Supplementary Prospectus and Base Prospectus.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings